Hello world! Kavli Institute for Nanoscience Discovery, Oxford University of Oxford Department of Biochemistry at Oxford University #malaria #vaccine #research #science #trial #FightMalaria #MalariaAwareness #MalariaPrevention #MalariaTreatment

Jo and Andrew from our clinical team explain #malaria challenge clinical trials - check out their great new video below 👇

#MeetTheResearcher This week's star researcher is Sarah Silk from Department of Biochemistry at Oxford University. Sarah is working as a Senior Clinical Trials Immunologist at Simon Draper's Lab. Her research focuses on set up, conduct and immunological analyses of blood-stage #malaria vaccine clinical trials.

Clinical trials are critical to the development of malaria vaccines, please consider applying. #WorldMalariaDay #clinicaltrials lnkd.in/eD7RNiJ7

Clinical trials are critical to the development of malaria vaccines, please consider applying. #WorldMalariaDay #clinicaltrials

#MeetTheResearcher Happy to introduce Francesca Donnellan from Simon Draper's lab this week. #KavliOxford

We are #recruiting for a Project Manager to join our team. If you’re keen to join a dynamic translational research group in Oxford, focussed on #vaccines and #malaria, then do check out the link. Come and join us! 👇 draperlab.web.ox.ac.uk/vacancies

RH5.1 is the most advanced #vaccine for blood-stage #malaria, currently in Phase 2b field efficacy trial. Delighted here to share our data on how vaccine-induced human antibodies recognise RH5 and kill #malaria parasites, now published Cell. cell.com/cell/fulltext/…

#TuesdayReads Check out the Draper Group's latest publication! They explore how antibodies target PfRH5 to inhibit #malaria parasite invasion, providing insights for next-gen #vaccine design. Read more 👇doi.org/10.1016/j.cell… Simon Draper Department of Biochemistry at Oxford University Medical Sciences

Breakthrough in malaria research! 🚨 The RH5.1/Matrix-M™ vaccine shows 55% efficacy against blood-stage malaria in children and >80% against high parasite levels. Safe, well-tolerated, and a key step forward. 🔗kavli.web.ox.ac.uk/article/trial-… Medical Sciences University of Oxford The Kavli Foundation

#TuesdayReads New study from Simon Draper Group et al. reports the RH5.1/Matrix-M #malaria #vaccine showed 55% efficacy and strong #antibody responses with a delayed third-dose regimen in young children. 👇 thelancet.com/journals/lanin…

Our group's new BIO-006 clinical trial on #vivax #malaria is recruiting now in Oxford. The first trial in our OptiVivax consortium. Aiming to assess relapsing malaria infection - check out the link below 👇

Kavli Institute for Nanoscience Discovery, Oxford OptiVivax

#OptiViVax launches a first-in-kind clinical trial, BIO-006, with the Oxford Vaccine Group to investigate relapsing malaria infection caused by Plasmodium vivax. Find out more here: optivivax.web.ox.ac.uk/article/draper… Kavli Institute for Nanoscience Discovery, Oxford Medical Sciences University of Oxford The Kavli Foundation Department of Paediatrics

Great podcast by Andrew Duncan explaining our latest P. vivax malaria challenge clinical trial. Part of the #OptiVivax Consortium working with the Oxford Vaccine Group and Kavli Institute for Nanoscience Discovery, Oxford ovg.ox.ac.uk/studies/bio006 Department of Paediatrics Medical Sciences University of Oxford The Kavli Foundation

Congratulations to #KavliOxford Professors Molly Stevens DBE, Simon Draper and Matt Higgins (Matt Higgins) on being elected Fellows of the Academy of Medical Sciences 2025. Read the Academy of Medical Sciences news article 👇 lnkd.in/dzqNYeZr